IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ZUIN, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.118
NA - Nord America 10.220
AS - Asia 8.361
SA - Sud America 826
AF - Africa 185
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 5
Totale 32.743
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.900
GB - Regno Unito 6.543
SG - Singapore 2.614
CN - Cina 2.525
IT - Italia 1.489
DE - Germania 1.267
SE - Svezia 870
RU - Federazione Russa 868
HK - Hong Kong 769
BR - Brasile 607
VN - Vietnam 586
FR - Francia 483
TR - Turchia 427
IN - India 343
UA - Ucraina 337
KR - Corea 315
IE - Irlanda 309
NL - Olanda 298
BD - Bangladesh 245
FI - Finlandia 236
CA - Canada 223
EU - Europa 156
ID - Indonesia 130
JP - Giappone 93
DK - Danimarca 90
PL - Polonia 77
CI - Costa d'Avorio 64
CO - Colombia 64
AR - Argentina 54
PH - Filippine 47
IQ - Iraq 45
GR - Grecia 41
MX - Messico 39
PK - Pakistan 34
ES - Italia 32
SA - Arabia Saudita 32
AU - Australia 26
BE - Belgio 26
CH - Svizzera 25
ZA - Sudafrica 25
VE - Venezuela 24
AT - Austria 23
CL - Cile 23
EC - Ecuador 23
UZ - Uzbekistan 20
NO - Norvegia 19
MA - Marocco 16
EG - Egitto 14
CZ - Repubblica Ceca 13
PY - Paraguay 13
TW - Taiwan 13
RO - Romania 12
IR - Iran 11
TH - Thailandia 11
KE - Kenya 10
AE - Emirati Arabi Uniti 9
IL - Israele 9
JM - Giamaica 9
JO - Giordania 9
KZ - Kazakistan 9
NP - Nepal 9
OM - Oman 9
PT - Portogallo 9
CR - Costa Rica 8
MY - Malesia 8
TN - Tunisia 8
HU - Ungheria 7
LV - Lettonia 7
PE - Perù 7
SC - Seychelles 7
AZ - Azerbaigian 6
BG - Bulgaria 6
HN - Honduras 6
LK - Sri Lanka 6
NG - Nigeria 6
UY - Uruguay 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
PR - Porto Rico 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BO - Bolivia 4
CG - Congo 4
CY - Cipro 4
DZ - Algeria 4
ET - Etiopia 4
GT - Guatemala 4
LB - Libano 4
LY - Libia 4
MD - Moldavia 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
LU - Lussemburgo 3
PA - Panama 3
SI - Slovenia 3
AL - Albania 2
BS - Bahamas 2
BW - Botswana 2
CM - Camerun 2
CV - Capo Verde 2
Totale 32.845
Salva come PNG Salva come JPEG
Città #
Southend 6.321
Singapore 1.546
Houston 1.446
Ashburn 854
Hong Kong 725
Chandler 671
Ann Arbor 616
Milan 551
Beijing 520
San Jose 511
Seattle 498
Dallas 383
Wilmington 342
Princeton 340
Dublin 306
Council Bluffs 267
Hanover 235
Fairfield 232
Redmond 224
Frankfurt am Main 208
Dearborn 200
Jacksonville 190
Los Angeles 186
Ho Chi Minh City 168
Santa Clara 168
Bengaluru 161
Lauterbourg 157
Nanjing 156
Woodbridge 155
Toronto 141
New York 140
Hanoi 128
Sakarya 128
Moscow 127
Des Moines 125
Mountain View 122
Buffalo 115
Guangzhou 112
Grafing 100
Boardman 95
Shanghai 93
Hefei 87
Serra 81
Cambridge 78
Columbus 76
Jinan 76
Helsinki 74
Jakarta 72
Berlin 70
Andover 66
The Dalles 65
Abidjan 63
Tokyo 63
São Paulo 62
Warsaw 62
Munich 60
Dong Ket 57
Shenyang 57
Istanbul 55
Bogotá 54
Cangzhou 53
Tianjin 53
Rome 52
Changsha 51
Somerville 51
Phoenix 48
Seoul 47
Bitonto 42
Nanchang 42
Redwood City 42
Hebei 40
Athens 35
Da Nang 34
Shenzhen 32
Fuzhou 30
Hangzhou 30
San Diego 30
London 28
Florence 27
Zhengzhou 26
Eitensheim 24
Haiphong 24
Nuremberg 24
Rio de Janeiro 24
Washington 23
Brussels 22
Turin 22
Brooklyn 21
Jiaxing 21
Kent 21
Kiez 21
Montreal 21
Saint Petersburg 21
Kunming 20
Falls Church 19
Naples 19
Chicago 18
Fremont 18
Orem 18
Ottawa 18
Totale 22.253
Salva come PNG Salva come JPEG
Nome #
Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic Fatty liver disease 1.640
Forecasting Hepatitis C liver disease burden on real life data: Does the hidden iceberg matter to reach the elimination goals? 682
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy 552
CA.ME.LI.A. An epidemiological study on the prevalence of cardiovascular, metabolic, liver and autoimmune diseases in Northern Italy 418
Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy 383
null 363
X chromosome monosomy : a common mechanism for autoimmune diseases 355
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 348
Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis 344
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 339
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 337
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 321
Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis 311
Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis 309
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status 289
Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis 283
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 283
X monosomy in female systemic lupus erythematosus 280
Uno studio longitudinale sull’incidenza di eventi cardiovascolari in una popolazione del nord Italia 273
A minimally invasive technique for the evaluation of the regulatory steps of the two major pathways of bile acid synthesis 270
ABCB4 mutations in adult patients with cholestatic liver disease : impact and phenotypic expression 269
Association of non-alcoholic fatty liver disease and cardiometabolic risk factors with early atherosclerosis in an adult population in Southern Italy 266
The unfinished business of primary biliary cirrhosis 265
Antibodies to carbonic anhydrase II in antimitochondrial antibody-negative primary biliary cirrhosis: a negative study 264
Acute liver and renal failure during treatment with buprenorphine at therapeutic dose 262
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 259
Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis 258
Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis 251
Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis 251
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis 248
T-cell receptor polymorphism in primary biliary cirrhosis 247
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 246
Geographic clusters of primary biliary cirrhosis 244
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 243
Sieroepidemiologia delle epatiti virali a trasmissione enterica (HAV e HEV) in Italia: progetto CAMELIA 241
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 236
Analysis of fatiguability in patients affected by Primary Biliary Cirrhosis by means of Transcranial Magnetic Stimulation 234
Exacerbation of chronic hepatitis D during interferon alpha administration 229
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) 226
Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions 224
Blood fetal microchimerism in primary biliary cirrhosis 219
Neurophysiology of fatigue in primary biliary cirrhosis suggests a central origin and a motivational impairment 218
Treatment with PEG-interferon and ribavirin for chronic hepatitis C does not decrease neutrophil and monocyte activity 218
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 218
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 216
Bile acid synthesis: In vivo evaluation of the two metabolic pathways in normal human subjects and in patients with primary biliary cirrhosis 215
Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma : a single European center experience of 426 patients 215
Primary biliary cirrhosis : solving the enigma 214
Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population. CA.ME.LI.A study 7 year follow-up 213
Genetic variants of the endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity 213
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 212
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 212
Patients with primary biliary cirrhosis do not show post-exercise depression of cortical excitability 211
Lithogenic bile after conjugated estrogen 207
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis : a multicenter study of 664 patients and 1992 healthy controls 206
Serum autoantibodies: a road map for the clinical hepatologist 204
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy : a case report 204
Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study 204
Lack of PBC-specific antimitochondrial antibodies in patients with Chlamydia pneumoniae infection 202
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 199
Genetics and geoepidemiology of primary biliary cirrhosis : following the footprints to disease etiology 196
Effects of a preparation containing a standardized ginseng extract combined with trace elements and multivitamins against hepatotoxin-induced chronic liver disease in the elderly 193
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 191
Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease 190
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 190
Serum levels of soluble interleukin 2 receptor a in patients with primary biliary cirrhosis 189
Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class A liver cirrhosis 187
A case of isoniazid-induced delirium 187
A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation 186
Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy 185
Intraoperative Ultrasound Score to Predict Recurrent Hepatocellular Carcinoma After Radical Treatments 184
Renal safety in 3264 HCV patients treated with DAA-based regimens : results from a large Italian real-life study 184
Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial 183
Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: an in vitro study 182
Duodenogastric reflux: correlations among bile acid pattern, mucus secretion, and mucosal damage 181
Controlled study of the effects of tiropramide on biliary dyskinesia 180
Caratterizzazione della "diabesità" in una popolazione del nord Italia: un'analisi epidemiologica 179
Role of ABCB4 gene mutations in hepatobiliary diseases of the adult : the experience of a liver Unit in Milan 178
Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis 178
Antibodies to hepatitis C virus in primary biliary cirrhosis 178
Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease) 178
A longitudinal study on the incidence of cardiovascular events in a population of Northern Italy 176
Successful liver transplantation from a donor with chromosomal abnormality (45,XO) 176
Gastrointestinal tolerability of ibuprofen administered in two pharmaceutical formulations 174
Genes and (auto)immunity in primary biliary cirrhosis 172
Individualized treatment of genotype 1 Naïve patients : an Italian multicenter field practice experience 170
The bile duct cell: A bully or a victim? 168
Anti-mitochondrial antibody-negative primary biliary cirrhosis 167
Laparoscopic thermoablation for hepatocellular carcinoma in patients with liver cirrhosis : an effective procedure for tricky tumors 166
LAPAROSCOPY WITH LAPAROSCOPIC ULTRASOUND FOR PRETREATMENT STAGING OF HEPATOCELLULAR CARCINOMA : A PROSPECTIVE STUDY 165
The chemical pathway to primary biliary cirrhosis 162
Study of corneal copper deposits in Wilson's disease by in vivo confocal microscopy 162
Innate immunity and primary biliary cirrhosis 161
Interferon alpha and its contribution to autoimmunity 161
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients 160
2-year effectiveness and safety of Tenofovir in 302 NUC-naive patients with chronic hepatitis B : a multicenter european study in clinical practive 159
2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice 159
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy 158
Serum anti-phospholipid antibody prevalence and cardiovascular significance in the general population of the camelia study 157
Gallstone dissolution after 6 months of ursodeoxycholic acid (UDCA): effectiveness of different doses 156
Totale 24.571
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.030
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021948 0 0 0 0 0 0 0 0 0 0 727 221
2021/20222.711 228 208 131 269 162 202 179 169 308 289 205 361
2022/20232.397 315 235 176 308 288 445 50 120 259 74 87 40
2023/20241.464 51 143 91 91 381 98 70 86 31 76 148 198
2024/20253.751 168 361 89 399 271 184 167 377 205 353 319 858
2025/20268.268 744 488 957 655 938 617 1.116 536 914 627 676 0
Totale 34.187